Víctor Cervera-Carrascón

After a Master of Pharmacy with a thesis on oncolytic viruses in Spain, Victor started his PhD studies in the field of immunotherapy taking part in a EC-sponsored industrial Marie Skłodowska-Curie consortium between actors in Netherlands and Finland. Most of his time was spent at TILT Biotherapeutics where he worked on the use of oncolytic viruses to enable immune checkpoint blockade and other T-cell related approaches. The uniqueness of the Marie Curie PhD programme linking cutting edge science with biotech business allowed him to develop a solid background in scientific, clinical, and industrial aspects of cancer immune therapies. In late 2018, Victor joined the TILT-team as the Head of Immunology. He continues to carry out research, participate in translating preclinical success into clinical trials, as well as support business development activities.